aivlosin
eco animal health europe limited - tilvalosina - antiinfectives per uso sistemico, antibatterici per uso sistemico, macrolidi - pheasants; chicken; turkeys; pigs - pigstreatment e methaphylaxis di animali della specie suina polmonite enzootica;trattamento di porcino enteropatia proliferativa (ileitis);il trattamento e la methaphylaxis di dissenteria suina. chickenstreatment e methaphylaxis di malattie respiratorie associate con mycoplasma gallisepticum in polli. pheasantstreatment di malattie respiratorie associate con mycoplasma gallisepticum. turkeystreatment di malattie respiratorie associate con tylvalosin ceppi sensibili di ornithobacterium rhinotracheale nei tacchini.
fatromectin 5 mg /ml ,soluzione pour on per bovini
eco animal health europe limited - ivermectina - ivermectina - 5 milligrammo (i), ivermectina - 5 mg - ivermectin
ecomectin 10 mg/ml
eco animal health europe limited - ivermectina - ivermectina - 10 milligrammo (i), ivermectina - 10 mg - ivermectin
vectimax 6mg/g premiscela per alimenti medicamentosi
eco animal health europe limited - ivermectina - ivermectina - 6 mg/g - ivermectin
fatromectin 6mg/g polvere orale
eco animal health europe limited - ivermectina - ivermectina - 6 milligrammo/g, ivermectina - 6 mg/g - ivermectin
avatar 18,7 mg/g
eco animal health europe limited - ivermectina - ivermectina - 18.7 milligrammo/grammo, ivermectina - 18.7 mg/g, ivermectina - 18.7 mg - ivermectin
ecomectin pour-on bovini
eco animal health europe limited - ivermectina - ivermectina - 5 milligrammo (i), ivermectina - 5 mg/ml, ivermectina - 5 mg - ivermectin
vectimax 1%
eco animal health europe limited - ivermectina - ivermectina - 10 milligrammo (i), ivermectina - 10 mg - ivermectin
vectimec 10 mg/ml
eco animal health europe limited - ivermectina - ivermectina - 10 milligrammo (i), ivermectina - 10 mg - ivermectin
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - fibrosi cistica - altri prodotti per il sistema respiratorio - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 e 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 e 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.